LBRX trades 15.2% below Wall Street's consensus target of $39.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LBRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, LB Pharmaceuticals Inc Common Stock (LBRX) has a Wall Street consensus price target of $39.50, based on estimates from 1 covering analysts. With the stock currently trading at $34.29, this represents a potential upside of +15.2%. The company has a market capitalization of $983M.
Analyst price targets range from a low of $36.00 to a high of $45.00, representing a 23% spread in expectations. The median target of $38.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LBRX trades at a trailing P/E of -34.3x. Analysts expect EPS to grow -154.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
ATHAAthira Pharma, Inc. | $17M | $4.34 | — | — | — | — | — |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
AXSMAxsome Therapeutics, Inc. | $12.9B | $249.76 | $262.38 | +5.1% | Buy | — | 26 |
INTRInter & Co, Inc. | $2.5B | $5.59 | $9.40 | +68.2% | Buy | 1.4x | 6 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
NRXPNRx Pharmaceuticals, Inc. | $72M | $4.16 | — | — | — | — | — |
CRLCharles River Laboratories International, Inc. | $11.0B | $228.68 | $222.11 | -2.9% | Buy | 20.6x | 37 |
IQVIQVIA Holdings Inc. | $35.3B | $208.23 | $222.40 | +6.8% | Buy | 16.2x | 44 |
Quick answers to the most common questions about buying LBRX stock.
LB Pharmaceuticals Inc Common Stock (LBRX) has a consensus 12-month price target of $39.5, implying 15.2% upside from $34.29. The 1 analysts covering LBRX see moderate appreciation potential.
LBRX has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $39.5 implies 15.2% upside from current levels.
LBRX's current price is $34.29 with a consensus target of $39.5 (15.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $45 for LBRX, while the most conservative target is $36. The consensus of $39.5 represents the median expectation. These targets typically reflect 12-month expectations.
LBRX is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LBRX stock forecast based on 1 Wall Street analysts shows a consensus price target of $39.5, with estimates ranging from $36 (bear case) to $45 (bull case). The median consensus rating is "Buy".
Wall Street analysts are optimistic on LBRX, with a "Buy" consensus rating and $39.5 price target (15.2% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LBRX analyst price targets range from $36 to $45, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.